Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-9-21
pubmed:abstractText
To test the hypothesis that prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population.
pubmed:commentsCorrections
pubmed:keyword
http://linkedlifedata.com/resource/pubmed/keyword/ANTIBIOTICS, http://linkedlifedata.com/resource/pubmed/keyword/DRUGS, http://linkedlifedata.com/resource/pubmed/keyword/Demographic Factors, http://linkedlifedata.com/resource/pubmed/keyword/Developed Countries, http://linkedlifedata.com/resource/pubmed/keyword/Double-blind Studies, http://linkedlifedata.com/resource/pubmed/keyword/Europe, http://linkedlifedata.com/resource/pubmed/keyword/NETHERLANDS, http://linkedlifedata.com/resource/pubmed/keyword/Population, http://linkedlifedata.com/resource/pubmed/keyword/Population Characteristics, http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy, http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy Outcomes, http://linkedlifedata.com/resource/pubmed/keyword/Pregnant Women, http://linkedlifedata.com/resource/pubmed/keyword/Reproduction, http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology, http://linkedlifedata.com/resource/pubmed/keyword/Research Report, http://linkedlifedata.com/resource/pubmed/keyword/Studies, http://linkedlifedata.com/resource/pubmed/keyword/Treatment, http://linkedlifedata.com/resource/pubmed/keyword/Western Europe
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0306-5456
pubmed:author
pubmed:issnType
Print
pubmed:volume
106
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
652-7
pubmed:dateRevised
2006-11-15
pubmed:otherAbstract
PIP: This multi-center, randomized, double-blind, placebo-controlled trial aimed to determine whether prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population. A total of 168 eligible women attending the antenatal clinics of 12 hospitals in Netherlands participated in the study. Clindamycin 2% vaginal cream was administered to 83 women, and placebo cream to 85 women, daily for 7 days at 26 and 32 weeks of gestation. Results of the study showed no difference in the overall preterm birth between clindamycin (23%) and placebo (18%) in the intention-to-treat analysis. In the subgroup, which completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (9%) compared to the placebo group (1.4%). Moreover, occurrence of neonatal infectious morbidity was higher in the clindamycin group (5/83 vs. 0/85; P 0.05). In conclusion, clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labor.
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.
pubmed:affiliation
Department of Obstetrics and Gynaecology, Diaconessenhuis Meppel, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study